SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that the company has published its 2025 ESG (Environmental, Social, and Governance) Report, which consolidates ESG information from its subsidiary German CDMO company IDT Biologika. The company plans to elevate its ESG performance and future strategies to meet global standards and strengthen stakeholder trust through the integrated ESG management system. The report is available on the company’s ESG website: https://esg.skbioscience.com/kr/

In the report, SK bioscience systematically integrates and presents sustainability practices, strategies, and key performance indicators for the last year.

Notably, the report reflects global ESG disclosure trends and applies the European Sustainability Reporting Standards (ESRS) double materiality framework, categorizing material issues by social and financial impact.

The company also introduced the IRO (Impact, Risk, Opportunity) assessment for the first time to analyze the influence of sustainability topics on the environment/ society, and business.

From an environmental and social perspective, five key material topics were identified: ▲attracting and developing talent ▲ensuring product safety and quality ▲improving access to medicines ▲managing hazardous and pollutant substances ▲upholding ethical standards and compliance.

From the financial perspective, three key material topics are selected: ▲governance ▲strategy ▲risk management. The company disclosed corresponding strategies and key achievements for each topic, aligned with its management activities.

In particular, the information related to ‘access to medicines’ was significantly expanded to reflect the company’s responsibilities as a global vaccine manufacturer. The report highlights SK bioscience’s commitment to corporate social responsibility by detailing every effort to improve access to medicines such as ▲strategies for expanding global vaccine supply ▲improving pricing accessibility ▲supporting vaccine distribution in low- and middle-income countries (LMICs).

SK bioscience manages ESG-related risks and opportunities at its ESG Committee under the Board of Directors. The company’s ESG task forces and working group also systematically implements action plans to create sustainable corporate value.

As part of its environmental commitments, the company focuses on environmental management, greenhouse gas reduction, and strengthening environmental impact systems.

In terms of social efforts, SK bioscience promotes employee well-being, enhances human rights practices, manages a sustainable supply chain, contributes to local communities, and fosters a culture of health and safety.

In governance, the company ensures transparency and responsible management by operating an independent and expert Board of Directors, reinforcing ethical management, and upgrading internal control systems.

Recognized for its ESG performance, SK bioscience received an ‘A’ rating for the third consecutive year from the Korea Institute of Corporate Governance and Sustainability (KCGS) and maintained an ‘A’ rating from MSCI ESG for two consecutive years.

Jongsoo Park, Head of the Sustainability Management Division at SK bioscience, said, “This year’s report reinforces transparency based on consolidated disclosure aligned with global standards. We will continue to meet the demands of global sustainability and fulfill our duty and responsibilities as a global enterprise.”